Skip to Main Content

Paper Details

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
Clinical Cancer Research
7
2022
AOE, AOEs, Advanced Gastrointestinal Stromal Tumors, GIST, KIT, KIT ex11, KIT exon 11, KIT exon 9, KIT mutations, Patients, Ponatinib, V654A, advanced GIST, arterial occlusive events, circulating tumor DNA, ctDNA, ex11, gastrointestinal stromal tumors, mutated ctDNA, patients, plasma, pneumonia, ponatinib, pulmonary embolism, tumor, tyrosine, tyrosine kinase, venous thromboembolic events
Author NameAffiliation
John Graeme HodgsonClinical Research, ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • 1 - 1

Datasets

Release 1.2